TG ImmunoPharma Receives FDA Approval to Initiate Clinical Trial for TGI-6 Bispecific Antibody
Tuesday, June 20, 2023
TG ImmunoPharma has announced that the FDA has approved the clinical investigation of TGI-6, for the development of breakthrough bispecific antibody.
TGI-6 is a novel antibody developed to target both tumour-associated antigens (TAA) and CD3 molecules. This dual targeting mechanism is designed to enhance anti-tumour responses. By binding to TAAs, which are specific to cancer cells, TGI-6 can directly recognise and attack tumour cells.
TGI-6, a novel therapeutic agent, has been specifically engineered to uphold potent cytotoxic effects while mitigating the potential for cytokine release syndrome (CRS). TGI-6 has demonstrated superior antitumor activity and safety in preclinical studies.
TGI-6 TAA is highly expressed in several solid tumours, including colon cancer, breast cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, pancreatic cancer and many others. This makes TGI-6 a promising candidate for the treatment of many solid tumours.
Preclinical investigations have showcased the remarkable potential of TGI-6, as it achieved complete regression of tumours in animal models of colourectal cancer following a single administration. TGI-6 is specifically designed to uphold potent cytotoxic activity while mitigating the potential for cytokine release syndrome (CRS).
